Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
15,376,559
-
Total 13F shares
-
2,087,877
-
Share change
-
+1,128,274
-
Total reported value
-
$7,835,456
-
Price per share
-
$3.74
-
Number of holders
-
15
-
Value change
-
+$4,246,540
-
Number of buys
-
12
-
Number of sells
-
1
Institutional Holders of Grace Therapeutics, Inc. - Common Stock (GRCE) as of Q4 2024
As of 31 Dec 2024,
Grace Therapeutics, Inc. - Common Stock (GRCE) was held by
15 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,087,877 shares.
The largest 10 holders included
ADAR1 Capital Management, LLC, AIGH Capital Management LLC, BANK OF AMERICA CORP /DE/, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, NATIONAL BANK OF CANADA /FI/, MORGAN STANLEY, Tower Research Capital LLC (TRC), and Royal Bank of Canada.
This page lists
15
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.